PHILADELPHIA, Dec. 7, 2018 /PRNewswire/ -- Brianna Wronko, CEO of Group K Diagnostics (GKD), a healthcare innovator revolutionizing patient care with accurate, fast and affordable diagnoses, has been elected to the Philadelphia Startup Leaders Board.
Wronko has a BSE in Bioengineering from the University of Pennsylvania, and seven years of research experience in biotechnology. She is well versed in FDA processes and spearheads GKD's technological development and company vision.
"As a young professional that's active in the startup community, I look forward to representing other biotech entrepreneurs in the Philadelphia area," said Wronko. "It is a great honor to be nominated to the Philadelphia Startup Leaders Board, and I hope my unique perspective can support the group's mission to help current and future founders succeed in Philadelphia and beyond."
Philly Startup Leaders is an active community of startup entrepreneurs that helps connect, educate, and develop the members of Greater Philadelphia's startup community. They supply startups with the resources and connections they need, with a vision of building a world-class ecosystem of innovators and entrepreneurs in the Philadelphia region.
The announcement comes on the heels of Wronko's recognition as part of Philadelphia Business Journal's 2018 Women of Distinction, as well as the commencement of Part II of GKD's liver function clinical trial at the University of Pennsylvania Liver Disease Clinic and the securement of $2M in Series A funding.
About Group K Diagnostics
Group K Diagnostics is revolutionizing patient care with accurate, fast and affordable diagnoses. Group K's microfluidic point-of-care device, called the MultiDiagnostic, provides test results in 20 minutes, allowing patients to have direct access to their medical results and enabling doctors to adjust medical treatments in a timely manner. The device has the potential to drastically improve quality of patient care. CEO Brianna Wronko founded the Philadelphia-based company in 2016.
Since its invention, Group K's innovation has generated praise in the healthcare and technology industries. Group K was named 2017 Best of the Best by MABA and Most Innovative Company of the 2017 Heart Science Forum. Wronko has also received recognition as the 2018 Spring PACT TiE Top Pitch Event Winner, winner of the technology category of the 2018 Stellar Startup awards, and the recipient of various other grants and awards.
Media Contact: Kim Cox
215-867-8600 ext. 220
SOURCE Group K Diagnostics